sign uplog in
Want to go ad-free? Find out how, here.

New Zealand headquartered maker of breathing equipment Fisher & Paykel Healthcare faces 'unprecedented' demand for its products as virus sweeps the globe

New Zealand headquartered maker of breathing equipment Fisher & Paykel Healthcare faces 'unprecedented' demand for its products as virus sweeps the globe

A New Zealand headquartered company making breathing equipment has faced unprecedented demand for its products amid the global pandemic and associated respiratory problems.

Fisher & Paykel Healthcare on Monday reported a record profit of $287.3 million for the year to March, up 37% on the profit last year.

Operating revenue was $1.26 billion, up 18% over last year.

Shareholders will get a final dividend of 15.5 cents per share, an increase of 15% on the final dividend last year. This brings the total dividend for the year to 27.5 cents per share, an increase of 18% on last year. 

And the company's expecting much more in the year ahead, with a forecast that revenues in the financial year now under way could be close to $1.5 billion and net profit may be as much as $340 million.

The Fisher & Paykel Healthcare shares were again in demand on the NZX on Monday, driving up nearly 4% to over $33.

The company said the increase in revenue in the financial year to March was largely driven by growth in the use of the company’s 'Optiflow' nasal high flow therapy, demand for products to treat Covid-19 patients, and strong hospital hardware sales throughout the course of the year.

"The 2020 financial year was already on track to deliver strong growth before the coronavirus impacted sales," managing director Lewis Gradon said.

"Beginning in January, the demand for our respiratory humidifiers accelerated in a way that has been unprecedented."

Gradon said with new processes, new procedures and new ways of working safely, "we managed to double and in some instances triple, output for some of our hospital hardware products over just a few months at the end of the year. I’m incredibly proud of our people and their unyielding commitment to doing the right thing for patients.”

In terms of the year ahead, Gradon said due to significant uncertainty in the extent and duration of the impact of Covid-19 on global demand for the company's products, it had made some assumptions to allow us it to provide "some guidance" for the full year to March 2021.

"As a result, our guidance is provided on the basis that global hospitalisations due to Covid-19 peak for the first quarter of this financial year, and hospitalisations for respiratory-related illnesses and OSA [obstructive sleep apnoea]  diagnostic activity steadily return to normal by the end of our first half. On this basis and at current exchange rates, full year operating revenue for the 2021 financial year would be approximately $1.48 billion and net profit after tax would be approximately $325 million to $340 million.

"Our assumption for guidance is not a prediction of the course of Covid-19 around the world. We are continuing to grow manufacturing capacity of hospital products during our 2021 financial year to ensure a further increase in supply of our respiratory products is available if required," he said.

Gradon said construction was complete on the company's fourth manufacturing building in New Zealand.

"As we bring forward capital expenditure spending for new product tooling and manufacturing capacity we expect capital expenditure for the 2021 financial year to be approximately $160 million."

We welcome your comments below. If you are not already registered, please register to comment.

Remember we welcome robust, respectful and insightful debate. We don't welcome abusive or defamatory comments and will de-register those repeatedly making such comments. Our current comment policy is here.


I have been a shareholder for over 15 years. If only NZ had a few more companies of its calibre. It spends a great deal on R&D, as it must to remain globally competitive.

Same here, although not quite as long as you. They've had a great run but at a PE of 50+ (factoring in the latest projections) and uncertainty about how long C19 will persevere (H1N1 vanished as suddenly as it arrived in 1918) the price is getting a bit fizzy.

Should have kept the 20k shares I bought as my first share purchase over 10 years ago at around $1.90! I thought I had done fabulously when they were triple that a few year later, now that's a 17 bagger plus...

One of NZs true success stories, built on intelligent ideas from intelligent people. Am amazed it's still domiciled in a country that does everything it can to destroy productivity.

Ha, the share investors lament ... if only I'd waited/not waited. You would likely have eventually been forced to quit some if you'd didn't want to be too heavily overweight to FPH. The current run up put me in that position and I wanted to be overweight cash with C19 bearing down so I recently quit about 20% of my holding at just under $30, currently sitting at $33.39. My average buy price over the years is $2.60 so I'm happy. As you say a truely great company. With the added bonus of having a strong element of currency hedge.

Gonna be a bigger star in the coming years, for sure. Hope they keep innovating and modernising.

Also big enough now to attract the attention of serious venture capital money.

Sold 2/3 of our holding at $23.10 before the lockdown. Owned them for 10 years so did pretty well. Temping to sell the rest

Purchased $11,000 worth of FPH in 2004. Now worth $167,000. Good dividends over this period too.

Wow, well done. I bought later but looks like a good stock to keep holding, especially in this environment of central bankers gone rabid.

In terms of employees, I think it attracts high quality engineers as there arent that many innovative companies in NZ they can work for.. I have some smart friends who started as grads, are still there 7 years later (all biomedical engineers) and are just really passionate about their work

Just to rub it - this morning Craigs have updated their target price to $38 on the back of this earnings upgrade !!

MacQ also upgraded TP on the back of this $37.59